Search

Search Constraints

You searched for: Author/Creator Armuzzi, A.

Search Results

1. Adalimumab in the Treatment of Immune-Mediated Diseases. (January 2014)

2. AF.49 DETERMINANTS OF COVID-19 VACCINE HESITANCY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): RESULTS OF A NATIONAL SURVEY OF THE ITALIAN IBD PATIENTS' ASSOCIATION (AMICI ONLUS). (September 2021)

3. AF.52 LONG-TERM OUTCOME OF ACUTE SEVERE ULCERATIVE COLITIS RESPONSIVE TO INTRAVENOUS STEROID: A MULTICENTER IG-IBD STUDY. (September 2021)

4. Anti-TNF Agents as Therapeutic Choice in Immune-Mediated Inflammatory Diseases: Focus on Adalimumab. (January 2014)

5. Fecal HMGB1 reveals microscopic inflammation in adult and pediatric patients with inflammatory bowel disease who are in clinical and endoscopic remission. (10th October 2016)

7. OC.02.5 EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF SWITCHING FROM ORIGINATOR INFILIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN A LARGE COHORT OF IBD PATIENTS. (1st October 2020)

8. OC.02.5 THE SOLUTE CARRIER LC22A4/OCTN1 AS A NOVEL IBD DETERMINANT AT THE MICROBE-HOST INTERFACE. (May 2022)

10. OC.04.3 REAL-LIFE VS TRIAL ACCESS TO BIOLOGIC THERAPY DIFFERENCES: A 2019-2020 EXPERIENCE IN AN ITALIAN TERTIARY IBD CENTER. (March 2023)